Aptamer Group Reports Revenue Growth and Strategic Advances in Interim Results

Aptamer Group Plc ( (GB:APTA) ) has provided an announcement.

Aptamer Group plc reported significant progress in its interim results for the six months ending December 2024, with revenue growth to £0.7 million and a reduced EBITDA loss. The company has made strategic board changes and is focusing on developing high-value Optimer assets with licensing potential. Key achievements include successful trials with Unilever for deodorant Optimers, validation of Alzheimer’s disease diagnostics, and advancements in drug delivery with AstraZeneca. The company is also progressing in fee-for-service projects, creating valuable assets in enzyme modulation and therapeutic delivery, which are expected to support future revenues. With a solid cash position and multiple new contracts, Aptamer is well-positioned to advance its strategy and deliver shareholder value.

More about Aptamer Group Plc

Aptamer Group plc operates in the life sciences industry, focusing on developing novel Optimer® binders. These binders are designed to facilitate innovation across various applications, including therapeutic development and diagnostics. The company targets partnerships with pharmaceutical and biotechnology companies to enhance its market presence.

YTD Price Performance: -10.81%

Average Trading Volume: 13,638,696

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £6.57M

Learn more about APTA stock on TipRanks’ Stock Analysis page.